IHU RespirERA relies on a robust network of industrial partners to support its projects.
This network spans various sectors such as biotechnology, pharmaceuticals, medical imaging, and medical technologies. These collaborations play a crucial role in the development and implementation of the institute's innovations. Among the main partners, those specialising in advanced diagnostics provide technologies that enable the early identification of biomarkers associated with respiratory diseases. Other partners from the pharmaceutical sector collaborate on clinical trials to test and validate new treatments based on personalised medicine. The development of robotics also enables access to the infinitesimally small, including early diagnosis of pulmonary tumors and molecular pathology.
The institute also engages with startups and DeepTech companies developing solutions based on artificial intelligence and machine learning, facilitating the analysis of large clinical and environmental data sets. These industrial collaborations allow for the rapid transfer of innovations from the laboratory to clinical practice, ensuring continuous improvement in patient care.
Non-exhaustive list of our industrial partners:
These partners contribute essential technological and scientific expertise to accelerate innovation in the diagnosis and treatment of respiratory diseases. This cooperation translates scientific discoveries into tangible clinical solutions and strengthens the valorisation of research outcomes.
IHU RespirERA is equipped with cutting-edge technologies, making it a pioneer in the fight against respiratory diseases.
Among the technological infrastructures are several biobanks, where biological samples from patient cohorts suffering from chronic diseases such as lung cancer, COPD (chronic obstructive pulmonary disease), and chronic interstitial diseases like Idiopathic Pulmonary Fibrosis are stored and analyzed. These resources are used to identify new diagnostic and prognostic biomarkers and to understand the molecular mechanisms underlying these pathologies.
The institute also has omics platforms (genomics, transcriptomics, proteomics, and exposomics) that allow for in-depth analysis of patients' biological profiles, an essential step in developing personalized treatments. Additionally, the institute utilizes artificial intelligence technologies to analyze large datasets from clinical and environmental sources, thereby optimizing early diagnosis and personalized care.
IHU RespirERA’s care services are also focused on the development of precision diagnostic and therapeutic techniques, particularly for early-stage lung cancer treatment.
These technological capabilities also include modeling and simulation tools that allow testing of complex medical interventions before they are implemented in patients, enhancing the safety and effectiveness of care.
